TR201815608T4 - Onkastatin m reseptörü antijeni bağlayıcı proteinler. - Google Patents

Onkastatin m reseptörü antijeni bağlayıcı proteinler. Download PDF

Info

Publication number
TR201815608T4
TR201815608T4 TR2018/15608T TR201815608T TR201815608T4 TR 201815608 T4 TR201815608 T4 TR 201815608T4 TR 2018/15608 T TR2018/15608 T TR 2018/15608T TR 201815608 T TR201815608 T TR 201815608T TR 201815608 T4 TR201815608 T4 TR 201815608T4
Authority
TR
Turkey
Prior art keywords
ser
gly
thr
leu
osmr
Prior art date
Application number
TR2018/15608T
Other languages
English (en)
Inventor
A Arnett Heather
S Escobar Sabine
T King Chadwick
Ching Lim Ai
Narayanan Saravanakumar
H Weinreb Paul
E Pederson Nels
Original Assignee
Kiniksa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals Ltd filed Critical Kiniksa Pharmaceuticals Ltd
Publication of TR201815608T4 publication Critical patent/TR201815608T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Mevcut buluş, anti-onkosfatin M reseptörü-ß (OSMR) antijen bağlayıcı proteinlerini, örneğin bunun antikorlarını ve fonksiyonel fragmanlarını, türevlerini, muteinlerini ve varyantlarını sağlar. OSMR antijeni bağlayıcı proteinleri, OSMR ve/veya IL-31'in OSMR'ye bağlanmasına müdahale eder. Bazı uygulamalarda anti-OSMR antijen bağlayıcı proteinleri, OSMR ile ilişkili hastalıklar ve bozuklukların araştırılmasında yararlı araçlardır ve OSMR ve OSMR ve/veya IL-31'in OSMR'ye bağlanması ile ilişkili hastalıklar ve bozuklukların tedavi edilmesine yönelik yöntemlerde özellikle yararlıdır.

Description

Tarifnamede yer alan herhangi bir dil kullaniminin, herhangi bir talep edilmemis unsurun bulusun uygulanmasi için zorunlu oldugu seklinde yorumlanmamalidir. ÖRNEKLER Heni gerçek heni de gelecege yönelik olarak verilen asagidaki örnekler, mevcut bulusun spesifik uygulamalarini veya özelliklerini tasvir etme amaciyla saglanmistir ve bulusun kapsamini sinirlandirmasi amaçlanmamistir. ÖRNEK 1: XENOMOUSE® Platformu Kullanilarak Anti-OSMR Antikorlarinin Üretilmesi Insan OSMR'ye karsi yönlendirilmis tamamen insan antikorlar, edildigi üzere) XENOMOUSE® teknolojisi kullanilarak olusturulmustur. OSMR'ye yönelik antikorlar olusturmak için XENOMOUSEG hayvanlarinin iki farkli susu, Örnegin XMGZ-KL ve XMG4-KL fareleri, (Amgen, Seattle, WA tarafindan hazirlanan) insan OSMR- Fc çözünebilir proteinleri ile bagisiklanmistir. Uygun bir miktarda immünojen (on pg/fare çözülebilir insan OSMR-Fc proteini), 3 Aralik 1996'da dosyalanmis U.S. Patenti Basvuru Uluslararasi Patent Basvurusu No. WO 98/24893 ve 21 Aralik yöntemlere göre XENOMOUSEG hayvanlarinin ilk immünizasyonu için kullanilmistir. Ilk immünizasyonun ardindan immünojen sonraki arttirici immünizasyonlari (bes ug/fare çözünür insan OSMR-Fc proteini), bir zaman çizelgesine göre ve farelerde uygun bir titrede anti-OSMR antikorunun indüklenmesi için gerekli bir sürede uygulanmistir. Ilk enjeksiyondan yaklasik dört hafta sonra serumlar toplanmis ve spesifik titreler ELISA ile belirlenmistir. XENOMOUSE® hayvanlarini titrelemek için kullanilan protokol su sekildedir: Costar 3368 ortamini baglayici plakalar, neutravadin @ 8 ug/mL (50 uL/kuyucuk) ile kaplanmis ve 4°C'de lXPBS/%0,05 azit içinde gece boyunca inkübe edilmistir. Plakalar, RO suyu ile TiterTek 3 devirli yikama kullanilarak yikanmistir. Plakalar, 250 pL 1XPBS/%1 süt kullanilarak bloke edilmistir ve oda sicakliginda en az 30 dakika inkübe edilmistir. Blok, RO suyu ile TiterTek 3 döngülü yikamasi kullanilarak yikanmistir. Daha sonra, 2 pg/mL'de 1XPBS/%l süt/lOmM Ca2+ (test seyrelticisi) içinde 50 pl/kuyucuk biyotinlenmis huOSMR-FNFH (Amgen, Seattle, WA tarafindan hazirlanmistir) yakalanmistir ve oda sicakliginda 1 saat inkübe edilmistir. Daha sonra RO suyu ile TiterTek 3 devirli yikama kullanilarak yikanmistir. Primer antikor için serumlar, 1:100 oranindan çiftler halinde 113 oranina titre edilmistir. Bu islem, 50 uL/kuyucuk test seyrelticisi içinde gerçeklestirilmis ve oda sicakliginda 1 saat inkübe edilmistir. Daha sonra RO suyu ile TiterTek 3 devirli yikama kullanilarak yikanmistir. Sekonder antikor, 50 uL/kuyucuk'ta test seyrelticisi içinde keçi anti Insan IgG FC HRP @ 400 ng/mL'dir. Bu antikor oda sicakliginda 1 saat inkübe edilmistir. Daha sonra RO suyu ile TiterTek 3 devirli yikama kullanilarak yikanmis ve kagit havlular üzerinde nazikçe kurutulmustur. Substrat için tek adimli TMB Çözeltisi (Neogen, Lexington, Kentucky) kullanilmis (50 uL/kuyucuk) ve substrat, 30 dakika boyunca oda sicakliginda gelismeye birakilmistir. Uygun titreler sergileyen hayvanlar tespit edilmistir. Bes XMG2KL hayvaninin, OSMR'ye karsi spesifik bir lgG immün yaniti verdigi tespit edilmistir. Bu hayvanlardan dalaklar ve drene olan lenf nodlari hasat edilmis ve hibridom üretimi için bir araya getirilmistir. Spesifik immün yanitlari veren bes XMG4KL hayvani, benzer sekilde hasat edilmis ve ayri bir füzyon taramasi olarak ilerletilmistir. Immün hayvanlardan elde edilen zenginlestirilmis B hücreleri, standart teknikler kullanilarak hibridomlar olusturmak için (Kohler ve dig., Nature 256, 495-7, ((Amerikan Tipi Kültür Koleksiyonu CRL-1580; Kearney ve dig., J. Hibridomlar daha sonra yüksek yogunlukta (kuyucuk basina çoklu farkli hibridom klonlari) 96 kuyucuklu doku kültür plakalarina yerlestirilmistir ve dört hafta boyunca büyütülmüstür. Hibridom hatti süpernatantlari, geçici olarak transfekte edilmis 293T hücreleri üzerinde ifade edilen tam uzunluklu insan ve sinomolgus OSMR'ye baglanma bakimindan Florometrik Mikrohacimli Test Teknolojisi (FMAT: Fluorometric Microvolume Assay Technology) (Applied Biosystems, Foster City, CA) ile taranmistir. Kisaca, 384 kuyucuklu FMAT plakalarinda, 3.000 OSMR hücreden olusan 40 ul'lik bir karisim, 15 uL'lik hibridom süpernatant ve 10 uL'lik anti-insan hafif zincir (hukappa/hulambda) Alexa etiketli sekonder antikoru (1,0 ug/mL final konsantrasyonu) ile birlestirilmistir. Plakalar daha sonra oda sicakliginda üç saat inkübe edilmis ve FMAT okuyucu kullanilarak flüoresan okunmustur. Bu taramalarda insan ve sinomolgus OSMR'ye baglanan 885 hibridom hatti tespit edilmistir. ÖRNEK 2: Insan OSMR Blogu Testleri OSMR antikorlarinin insan OSMR araciligiyla sinyallemeyi bloke etme kabiliyeti, ligand olarak insan onkostatin M (OSM) veya insan interlökin 31'in (IL-31) kullanildigi iki test kullanilarak belirlenmistir. Testler birlikte, antikorlarin OSM ve/Veya lL-3l'in baglanmasi yoluyla tetiklenen OSMR'nin sinyallemesini inhibe edip edemeyecegini belirlemek için kullanilmistir. Ilk taramada antikorlar, OSMR araciligiyla OSM'nin sinyalini bloke etme kabiliyetleri bakimindan degerlendirilmistir. Primer normal insan akciger fibroblastlarinin OSM ile uyarilmasi, STATB'ün fosforilasyonunu ve bunu takiben çekirdege translokasyonu indükler. Hücreler, Costar 384 kuyucuklu plakalarda kuyucuk basina 3000 hücrede ekilmis ve gece boyunca yapismaya birakilmistir. Hücreler, antikor süpernatanlari ile yirmi dakika boyunca ön isleme tabi tutulmustur ve daha sonra 80 pM insan OSM ile 30 dakika boyunca uyarilmistir. Hücreler, PBS içinde 3 kere yikanmis, %3,5 formaldehit çözeltisi ile sabitlenmis, yikanmis (PBST içinde 3 kere) ve %0,5 Triton X-100 çözeltisi ile geçirgen hale getirilmistir. Hücreler daha sonra bir saat boyunca bir anti-fosfoSTAT3 antikoru ile boyanmis, yikanmis ve bir AlexaFluor (tümü Cellomics'e ait HitKit içinde bulunur) ile konjüge edilmis antikor ile boyanmistir. Plakalar, bir Nükleer Yogunluk degeri ve bir Sitoplazmik Yogunluk degeri olusturmak için Cellomics tescilli algoritmasinin kullanilarak ArrayScan cihazinda okunmustur. Sonuçlar, söz konusu iki degerin arasinda fark olarak bildirilmistir ve ayrica en üst düzeyde uyarilmis hücreler ve ortam ile içeren kontrol verisine normallestirilmistir (POC). Ikinci testte antikorlar, insan lL-31RA4 ve OSMR'yi asiri ifade etmis stabil bir hücre hattinda OSMR yoluyla IL-3l'in proliferatif bir sinyalini inhibe etme kabiliyetleri bakimindan test edilmistir. BaF3 hücreleri, iki plazmid ile stabil bir sekilde transfekte edilmistir: pcDNA ve pcDNA3.l + huIL31RA4 (ZeoR). Murin IL-3'ün yoklugunda, bu hücre hatti, yalnizca insan lL-31'e yanit olarak çogalabilir ve bu nedenle anti-OSMR antikorlarinin bloke etme kabiliyetini degerlendirmek için spesifik olarak kullanilabilir. BaF3 hücreleri, 96 kuyucuklu plakalara kuyucuk basina 20.000 hücre yogunlugunda yerlestirilmistir. Antikorlar ve ligand (huIL-3l, Peprotech), 100 uL'lik bir son hacimde kuyucuklara ilave edilmistir ve plakalar, %5 COZ, 37C nemlendirilmis bölmede 72 saat boyunca inkübe edilmistir. Inkübasyonun ardindan her bir kuyucuga 20 uL Alamar Blue ilave edilmis ve plakalar yeniden inkübatöre koyulmustur. Plakalar, Alamar Blue ilavesinin sonrasinda bir Molecular Devices Vmax Plate reader (570-600 nm) üzerinde çesitli zaman noktalarinda okunmustur. Söz konusu iki teste ait sonuçlar asagida yer alan Tablo 4'te sunulmustur. 3000'den fazla hibridom süpernatanti bu iki testte bloklama kabiliyeti bakimindan taranmistir; en iyi 200 bloklayici, 4 noktali bir titrasyonda tekrar test edilmistir ve bunlardan 14'ü rekombinant protein üretimi ve baska testler için seçilmistir. Örnek niteligindeki üç antikor (antikor 1-3) için antikorlar, GSM ile indüklenen STAT3 translokasyonunu IL-3l ile indüklenen çogalmayi inhibe ettiginden daha fazla inhibe etmistir ve bazi antikorlarda da tam tersi görülmüstür. Ancak üç antikor` da, OSNI ve IL-3l aracili sinyallemesine karsi güçlü inhibitörlerdir. ÖRNEK 3: Sinomolgus OSMR Blogu Testleri OSMR antikorunun sinomolgus OSMR araciligiyla sinyallemeyi bloke etme kabiliyeti, ligand olarak insan OSM veya insan IL-31 kullanildigi iki test kullanilarak arastirilmistir. Ilk taramada antikorlar, bir primer bir böbrek epitelyal hücre hatti kullanilarak sinomolgus OSMR araciligiyla OSM'nin sinyalini bloke etme kabiliyetleri bakimindan degerlendirilmistir. Bu hücrelerin sinomolgus (sino) OSM ile uyarilmasi, STAT3'ün fosforilasyonunu ve bunu takiben çekirdege translokasyonu indükler. Hücreler, Costar 384 kuyucuklu plakalarda kuyucuk basina 3000 hücrede ekilmis ve gece boyunca yapismaya birakilmistir. Hücreler, antikor süpernatanlari ile yirmi dakika boyunca ön isleme tabi tutulmustur ve daha sonra 80 pM sino OSM ile 30 dakika boyunca uyarilmistir. Hücreler, PBS içinde 3 kere yikanmis, %3,5 formaldehit çözeltisi ile sabitlenmis, yikanmis (PBST içinde 3 kere) ve %0,5 Triton X-lOO çözeltisi ile geçirgen hale getirilmistir. Hücreler daha sonra bir` saat boyunca bir anti-fosfoSTAT3 antikoru ile boyanmis, yikanmis ve bir AlexaFluor (tümü Cellomics'e ait HitKit içinde bulunur) ile konjüge edilmis antikor ile boyanmistir. Plakalar, bir Nükleer Yogunluk degeri ve bir Sitoplazmik Yogunluk degeri olusturmak için Cellomics tescilli algoritmasinin kullanilarak ArrayScan cihazinda okunmustur. Sonuçlar, söz konusu iki degerin arasinda fark olarak bildirilmistir ve ayrica en üst düzeyde uyarilmis hücreler ve ortam ile içeren kontrol verisine normallestirilmistir (POC). Ikinci testte antikorlar, sino IL-3 IRA ve OSMR'yi asiri ifade etmis stabil bir hücre hattinda sinomolgus OSMR yoluyla IL-31'in proliferatif bir sinyalini inhibe etme kabiliyetleri bakimindan test edilmistir. Örnek Z'ye benzer sekilde BaF3 hücreleri, 96 kuyucuklu plakalara kuyucuk basina 20.000 hücre yogunlugunda yerlestirilmistir. Antikorlar ve ligand (sinomolgus IL-3l, kurum içi, Amgen, Seattle, WA), lOO uL'lik bir son hacimde kuyucuklara ilave edilmistir ve plakalar, %5 COZ, 37C nemlendirilmis bölmede 72 saat boyunca inkübe edilmistir. Inkübasyonun ardindan her bir kuyucuga 20 uL Alamar Blue ilave edilmis ve plakalar yeniden inkübatöre koyulmustur. Plakalar, Alamar Blue ilavesinin sonrasinda. Molecular Devices Vmax Plate reader (570-600 nm) üzerinde çesitli zaman noktalarinda okunmustur. Söz konusu iki teste ait sonuçlar, iki test için de gösterilen her bir antikor için IC50 degeri ile birlikte asagida yer alan Tablo 5'te sunulmustur. Sonuçlar, antikor` l, 2 ve 3'ün her birinin, OSM ve IL-3l aracili sinyallemesine karsi güçlü inhibitörler oldugunu dogrular. ÖRNEK 4: Anti-OSMR Antikorlarinin Epitop Gruplamasi (Binning) Anti-OSMR xenomouse antikorlarinin epitoplarini karakterize etmek üzere antikor rekabet çalismalari gerçeklestirilmistir. Birbiriyle rekabet eden antikorlarin hedef üzerinde ayni alana baglandiklari kabul edilir. Bu deneylerde OSMR veya alakasiz antikorlar, bir uygulama antikoruna (biyotinlenmis monovalent fare anti-insan IgG FC antikoru) önceden baglanmis streptavidin kapli Luminex boncuklari üzerinde yakalanmistir. OSMR antijeni veya tamponu (antijensiz) kuyucuklara ilave edilmistir ve bir prob antikoru her bir kuyucuga eklenmis ve bir PE etiketli monovalent fare anti-insan IgG FC antikoru ile tespit edilmistir. Her kuyucugun ortalama flüoresan yogunlugu ölçülmüstür. Tam referans için bkz. Jia ve dig., J. Immunol. tespit edilmesi, prob antikorunun diger OSMR antikorunun varliginda bile OSMR'ye baglanabildigini ve bunlarin ayri epitoplara baglandiklarini göstermistir. Asagida Tablo 6'da gösterildigi gibi en az üç kutu bulunmustur. ÖRNEK 5: Anti-OSMR Antikorlarinin Afinite Tayini Anti-OSMR antikorlarinin afiniteleri belirlenmistir. Antikorlar 1-3'ün (Ab 1-3) insan OSMR ile etkilesimini arastirmak için kinetik hiz sabitleri belirlenmistir. Biyosensör analizi, 25°C'de bir HBS-EP+ (1x) tampon sisteminde P20) bir CM5 sensör çipi içeren bir Biacore 3000 optik biyosensörü ile gerçeklestirilmistir. Tüm ayiraçlar, enjeksiyondan önce 8°C'de muhafaza edilmistir. Keçi anti-insan 2'ye standart amin kenetleme yoluyla sensör çipine immobilize edilmistir (~ ve etanolamin ile bloke edilmistir. hOSMR.FH, 150 nM'de yürütme tamponu içinde hazirlanmistir ve 0,617 nM'ye 3 kat seyreltilmistir. Antikorlar 1-3, yürütme tamponunda seyreltilmistir (0,25 ila 0,5 üg/mL). Antikorlar, 10 uL/dk'lik bir akis hizinda Akis Hücresi 2 üzerinden enjekte edilmistir (15 uL). Yaklasik 50 RU antikor yakalanmistir. Yüzey, stabilize olmaya birakilmistir (90 sn) ve daha sonra hOSMR'nin birlesme (5 dk) ve ayrismayi (5 dk) gözlemlemek için 50 uL/dk'lik bir akis hizinda Akis Hücre l xwe 2 üzerinden geçirilmistir. Numuneler, ikili halinde ve rastgele sirayla yürütülmüstür. Tampon analit boslari (0 nM hOSMR) numune enjeksiyonlarindan önce, enjeksiyonlarin arasinda ve enjeksiyonlardan sonra enjekte edilmistir. Antikorlar, 10 uL/dk'lik bir akis hizinda Akis Hücresi 2 üzerinden enjekte edilmistir (15 uL). Yaklasik 50 RU antikor yakalanmistir. Yüzey, stabilize olmaya birakilmistir (90 sn) ve daha sonra hOSMR'nin her bir konsantrasyonu (150), birlesme (5 dk) ve ayrismayi (1-2 saat) gözlemlemek için 50 uL/dk'lik bir akis hizinda Akis Hücre 1 ve 2 üzerinden geçirilmistir. Numuneler üçlü halinde yürütülmüstür. Tampon analit boslari (0 nM hOSMR) numune enjeksiyonlarindan önce ve enjeksiyonlardan sonra enjekte edilmistir. Yüzey, iki 10 mM glisin (pH 1,5, 50 uL) enjeksiyonu ile birlikte 50 uL/dk'lik bir akis hizinda rejenere edilmistir. Ardindan bir tampon bos enjeksiyon (15 sn) gerçeklestirilmistir. Veriler, Scrubber 2.0 ile asagidaki gibi analiz edilmistir. Akis Hücresi Z'den elde edilen veriler, Akis Hücresi 1'den (bos referans) elde edilen veriler çikarilmistir. Çikarilan referans veriler (2-1), daha sonra en yakin 0 nM konsantrasyon verisinden çikarilmistir (çift referansli). Çift referansli uzun ayrisma verileri, ayrisma hizi sabitini (kd) belirlemek için bir 1:1 oraninda baglanma modeline uydurulmustur. Bu ayrisma hizi sabiti, ayrisma hizi sabitini (ka) ve denge ayrisma sabitini (Kd) belirlemek için çift referansli kisa ayrisma verisinin bir 121 oraninda baglanma modeline uydurulmasi için bir uydurulmus parametre olarak kullanilmistir. Ayiraçlar, deney kosullari altinda iyi bir sekilde davranmistir ve veriler (bkz. asagida yer alan Tablo 7), bir lzl oraninda baglanma modelinde iyi bir sekilde uyum saglamistir. Antikor Antijen kd (1/Ms) Kd (1/s) Kd (pM) Ab2 huOSMR Ab2 huOSMR Insan OSMR'ye karsi yönlendirilmis tamamen insan antikorlar, asagida Örnek tarif edilen XENOMOUSE® teknolojisi kullanilarak üretilmistir. Antikor 1, 2 ve 3'ün her birinin, OSM ve/Veya lL-3l aracili sinyallemenin güçlü inhibitörleri oldugu görülmüstür. Antikor l, 2 ve 3'ün sekanslari (örn. Abl, Ab2, ve Ab3), belirlenmistir ve asagida Tablo 8'de belirtilmistir. Açiklama Sekans Abl-Agir Zincir nükleotidi caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggc ctcagtgaaggtctcctgcaaggcttctggatacaccttcaccagtt atgatatcaactgggtgcgacaggccactggacaggggcttgagtgg atgggatggatgaaccctaatagtggtaacacagactatgcacagaa gttccagggcagagtcaccatgaccaggaacatttccataagcacgg cctacattgagctgagcagcctgagatctgaggacacggccgtttat tactgtgcgagagatatggtggctgcgaatacggattactacttcta ctacggtatggacgtctggggccaagggaccacggtcaccgtctcct cagctagcaccaagggcccatcggtcttccocctggcgccctgctcc aggagcacctccgagagcacagcggccctgggctgcctggtcaagga ctacttccccgaaccgqtgacggtgtcgtggaathaggcgctctga ccagcggcgtgcacaccttcccagctgtcctacagtcctcaggactc tactccctcagcagcgtggtgaccgtgccctccagcaacttcggcac ccagacctacacctgcaacgtagatcacaagcccagcaacaccaagg tggacaagacagttgagcgcaaatgttgtgtcgagtgcccaccgtgc ccagcaccacctgtggcaggaccgtcagtcttcctcttccccccaaa acccaaggacaccctcatgatctcccggacccctgaggtcacgtgcg tggtggtggacgtgagccacgaagaccccgaggtccagttcaactgg tacgtggacggcgtggaggtgcataatgccaagacaaagccacggga ggagcagttcaacagcacgttccgtgtggtcagcgtcctcaccgttg tgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctcc aacaaaggcctcccagcccccatcgagaaaaccatctccaaaaccaa agggcagccccgagaaccacaggtgtacaocctgcccccatcccggg aggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggc ttctaccccagcgacatcgccgtggagtgggagagcaatgggcagcc ggagaacaactacaagaccacacctcccatgctggactccgacggct ccttcttcctctacagcaagotcaccgtggacaagagcaggtggcag caggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaa AbZ-Agir Zincir nükleotidi âlüd±&`"ââ`LQQßLJCܱüaJgIIgüLUJiCdÂQQUCLLÜdqLUU ata "âîüiuIC"'&NVaÇLgqLLLClßiüüüLjLJJJ?Lgli JL * ÇJ .im qt '&LüdîîdqqiiüiîîlûüilâdûîgCJÇ tt.-ii-iri It--«jJS~JJJJJJU-~-;TçtüâhiJ--tuüî ±:_t_ _1w__;_J:g:;uu;.tuggt-ttcuuci qjcjurstgctui ---i "tt--';;J- çujgtq-u;jtgîc-îjjJJ-îü-_ -I--~t11 UUJSCJJC'-W-;Q---CIÇÇ--I I_Ituu-J:UjtCÇîUJUQ_C-Ç tJ.îCCÇIuJ_I--Iljtjjt:u .qîiuuutriJ;r Ab3-Agir Zincir nükleotidi caggttcatctggtgcagtctggagctgaggtgaagaagcctggggc ctcagtgaaggtctcctgcaaggcttctggttacacctttaccagct atggtatcagctgggtgcgacaggcccctggacaagggcttgagtgg atgggatggctcagcacttacagtggtaacacaaactatgcacagaa gctccagggcagagtcaccatgaccacagacacatccacgagcacag cctacatggagctgaggagcctgagatctgacgacacggccgtgtat tactgtgcgagagggaacttCtactactacggtatggacgtctgggg ccaggggaccacggtcaccgtctcctcagctagcaccaagggcccat cggtcttccccctggcgccctgctccaggagcacctccgagagcaca gcggccctgggctgcctggtcaaggactacttccccgaaccggtgac ggtgtcgtggaactcaggcgctctgaccagcggcgtqcacaccttcc cagctgtcctacagtcctcaggactctactccctcagcagcgtggtg accgtgccctccagcaacttcggcacccagacctacacctgcaacgt agatcacaagcccagcaacaccaaggtggacaagacagttgagcgca aatgttgtgtcgagtgcccaccgtgcccagcaccacctgtggcagga ccgtcagtcttcctcttccccccaaaacccaaggacaccctcatgat ctcccggacccctgaggtcacgtgcgtggtggtggacgtgagccacg aagaccccgaggtccagttcaactggtacgtggacggcgtggaggtg cataatgccaagacaaagccacgggaggagcagttcaacagcacgtt ccgtgtggtcagcgtcctcaccgttgtgcaccaggactggctgaacg gcaaggagtacaagtgcaaggtctccaacaaaggcctcccagccccc atcgagaaaaccatctccaaaaccaaagggcagccccgagaaccaca ggtgtacaccctgcccccatcccgggaggagatgaccaagaaccagg tcagcctgacctgcctggtcaaaggcttctaccccagcgacatcgcc gtggagtgggagagcaatgggcagccggagaacaactacaagaccac acctcccatgctggactccgacggctccttcttcctctacagcaagc tcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgc Abl-Agir Zincir proteini QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEW MGWMNPNSGNTDYAQKFQGRVTMTRNISISTAYIELSSLRSEDTAVY YCARDMVAANTDYYFYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCS RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNW YVDGVEVHNÃKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTOKSLSLSPGK AbZ-Agir Zincir proteini QVQLVQSGAEVKKPGASVKVSCKÄSGYTFTSYEINWVRQÄTGQGLEW MGWMNPNSGYTGYAQKFQGRVTMTRNTSISTAYMEMSSLRSEDTAVY YCARDIVAANTDYYFYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCS RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK Ab3-Agir Zincir proteini QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEW MGWLSTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVY YCARGNFYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSEST AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV HNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAP VEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPGK Abl-Agir Zincir Degisken Bölgesi QVQLVQSGABVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEW MGWMNPNSGNTDYAQKFQGRVTMTRNISISTAYIELSSLRSEDTAVY YCARDMVAANTDYYFYYGMDVWGQGTTVTVSS AbZ-Agir Zincir Degisken Bölgesi QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEW MGWMNPNSGYTGYAQKFQGRVTMTRNTSISTAYMEMSSLRSEDTAVY YCARDIVAANTDYYFYYGMDVWGQGTTVTVSS Ab3-Agir Zincir Degisken Bölgesi QVHLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEW MGWLSTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVY YCARGNFYYYGMDVWGQGTTVTVSS Abl-Agir ZincirlZ SYDIN AbZ-Agir Zincir13 SYEIN Ab3-Agir Zincirl4 SYGIS Abi-Agir ZincirlS WMNPNSGNTDYAQKFQG AbZ-Agir Zincir16 WMGWMNPNSGYTGYAQKFQG Ab3-Agir Zincirl7 WLSTYSGNTNYAQKLQG Abl-Agir Zincirl8 DMVAANTDYYFYYGMDV AbZ-Agir Zincir19 DIVAANTDYYFYYGMDV Abl-Hafif 21 cagtctgtgctgactcagccaccctcagcatctgggacccccgggca nükleotidi ctcatctatactaataatcggcggccctccggggtccctgaccgatt ctctggctccaagtctggcacctcagcctccctggccatcagtgggc tccagtctgaggatgaggctgattatttctgtgcagcgttagatgac agtctgaatggtgtggtattcggcggagggaccaaactgaccgtcct aggccaaccgaaagcggcgccctcggtcactctgttcccgccctcct ctgaggagcttcaagccaacaaggccacactggtgtgtctcataagt gacttctacccgggagccgtgacagtggcctggaagqcagatagcag ccccgtcaaggcgggagtggagaccaccacaccctccaaacaaagca acaacaagtacgcggccagcagctatctgagcctgacgcctgagcag tggaagtcccacagaagctacagctgccaggtcacgcatgaagggag caccgtggagaagacagtggcccctacagaatgttca Ab2-Hafif nükleotidi cagtctgtgctgactcagccaccctcagcgtctgggacccccgggca gagggtcaccatctcttgttctggaagcaactccaacatcggaagta atactgtcaactggtaccaccagctcccaggaacggcccccaaactc ctcatctataatattaataagcggccctcaggggtccctgaccgatt ctctggctccaagtctggctcctcagcctccctggccatcagtgggc tccagtctgaggatgaggctgattattactgttcaacatgggatgac agcctggatggtgtggtattcggcggagggaccaagctgaccgtcct aggccaaccgaaagcggcgccctcggtcactctgttcccgccctcct ctgaggagcttcaagccaacaaggccacactggtgtgtctcataagt gacttctacccgggagccgtgacagtqgcctggaaggcagatagcag ccccgtcaaggcgggagtggagaccaccacaccctccaaacaaagca acaacaagtacgcggccagcagctatctgagcctgacgcctgagcag tggaagtcccacagaagctacagctgccaggtcacgcatgaagggag caccgtggagaagacagtggcccctacagaatgttca Ab3-Hafif nükleotidi gaaattgtgttgacgcagtctccaggcaccctgtctttgtctccagg ggaaagagccaccctctcctgcagggccagtcagagtgttagcagca gctacttagcctggtaccagcagaaacctggccaggthccaggctc ctcatctttggtgcttccagcagggccactggcatcccagacaggtt cagtggcagtgggtctgggacagacttcactctcaccatcagcagac tggagcctgaagattttgcagtgtattactgtcagcagtatggtagc tcgcctccgatcaccttcggccaagggacacgactggagattaaacg tacgqtggctgcaccatctgtcttcatcttcccgccatctgatgagc agttgaaatctggaactgcctctgttgtgtgcctgctgaataacttc tatcccagagaggccaaagtacagtggaaggtggataacgccctcca atcgggtaactcccaggagagtgtcacagagcaggacagcaaggaca gcacctacagcctcagcagcaccctgacgctgagcaaagcagactac gagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgag ctcgcccgtcacaaagagcttcaacaggggagagtgt Abl-Hafif Zincir proteini QSVLTQPPSASGTPGQRVTISCSGSSSNVGSNTVSWYQQLPGTAPKL LIYTNNRRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCAALDD SLNGVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLIS DFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAÂSSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS AbZ-Hafif Zincir proteini QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKL LIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDD SLDGVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLIS DFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQ WKSHRSYSCQVTHEGSTVEKTVAPTECS Ab3-Hafif Zincir proteini EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRL LIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGS SPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF YPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADY EKHKVYACEVTHQGLSSPVTKSFNRGEC Abl-Hafif Zincir Degisken QSVLTQPPSASGTPGQRVTISCSGSSSNVGSNTVSWYQQLPGTAPKL LIYTNNRRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYFCAALDD SLNGVVFGGGTKLTVLG AbZ-Hafif Zincir Degisken QSVLTQPPSASGTPGQRVTISCSGSNSNIGSNTVNWYHQLPGTAPKL LIYNINKRPSGVPDRFSGSKSGSSASLAISGLQSEDEADYYCSTWDD SLDGVVFGGGTKLTVLG Ab3-Hafif Zincir Degisken EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRL LIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGS SPPITFGQGTRLEIKR Abl-Hafif Zincir CDRl AbZ-Hafif 31 SGSNSNIGSNTVN Zincir CDRl Ab3-Hafif 32 RASQSVSSSYLA Zincir CDRl Abl-Hafif 33 TNNRRPS Zincir CDR2 AbZ-Hafif 34 NINKRPS Zincir CDR2 Ab3-Hafif 35 GASSRAT Zincir CDR2 Abl-Hafif 36 AALDDSLNGVV Zincir CDR3 AbZ-Hafif 37 STWDDSLDGVV Zincir CDR3 Ab3-Hafif 38 QQYGSSPPIT Zincir CDR3 ÖRNEK 7: Modifiye Edilmis Anti-OSMR Antikorlari Abl, Ab2 ve Ab3'ün modifiye edilmis versiyonlari olusturulmustur. Antikorlarin modifiye edilmis üç formu için de agir zincir C ucundaki lizin kaldirilmistir. Abl ve Ab2 için pozisyon 73'teki glikozilasyon alani, pozisyon 73'teki asparaginin bir aspartik asit ile ornatilarak kaldirilmistir. Bu varyantlar, Abl-N73D ve Ab2-N73D olarak adlandirilir. Modifiye edilmis sekanslar, asagida Tablo 9'da yer alir (modifiye edilmis nükleotitler ve amino asitlerin alti çizilmistir). Açiklama SEQ ID Sekans bl versiyon 2- Agir Zincir nükleotidi (N73D / C ucu silinmis) .1.Lm4tviigciun.: t; hacq: ..:".n:x atüdî_zt"5 55:'q~ç Ç]dejgîatjjtfjß-j-jsgi_ ua! Mifîî'i'üg n -îu1qi 'rateraa Ab2 versiyon 2- Agir Zincir nükleotidi (N73D / C ucu silinmis) caggtgcagctggtgcagtctggggctgaggtgaagaagcctggggc ctcagtgaaggtctcctgcaaggcttctggatacaccttcaccagtt atgaaatcaactgggtgcgacaggccactggacaagggcttgagtgg atgggatggatgaaccctaacagtggttacacaggctatgcacagaa gttccagggcagagtcaccatgaccagggacacctccataagcacag cctacatggaaatgagcagcctgagatctgaggacacggccgtgtat tactgtgcgagagatatagtggctgcgaatacggattactacttcta ttatggtatggacgtctggggccaagggaccacggtcaccgtctcct cagctagcaccaagggcccatcggtcttccccctggcgccctgctcc aggagcacctccgagagcacagcggccctgggctgcctggtcaagga ctacttccccgaaccggtgacggtgtcgtggaactcaggcgctctga ccagcggcgtgcacaccttcccagctgtcctacagtcctcaggactc tactccctcagcagcgtggtgaccgtgccctccagcaacttcggcac ccagacctacacctgcaacgtagatcacaagcccagcaacaccaagg tggacaagacagttgagcgcaaatgttgtgtcgagtgcccaccgtgc ccagcaccacctgtggcaggaccgtcagtcttcctcttccccccaaa acccaaggacaccctcatgatctcccggacccctgaggtcacgtgcg tggtggtggacgtgagccacgaagaccccgaggtccagttcaactgg tacgtggacggcgtggaggtgcataatgccaagacaaagccacggga ggagcagttcaacagcacgttccgtgtggtcagcgtcctcaccgttg tgcaccaggactggctgaacggcaaggagtacaagtgcaaggtctcc aacaaaggcctcccagcccccatcgagaaaaccatctccaaaaccaa agggcagccccgagaaccacaggtgtacaccctgcccccatcccggg aggagatgaccaagaaccaggtcagcctgacctgcctggtcaaaggc ttctaccccagcgacatcgccgtggagtgggagagcaatgggcagcc ggagaacaactacaagaccacacctcccatgctggactccgacggct ccttcttcctctacagcaagctcaccgtggacaagagcaggtggcag caggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaa ccactacacgcagaagagcctctccctgtctccgggt Ab3-Agir Zincir nükleotidi (C silinmis) ir'wî`1'34 .JJUIJfÜuVQJJ"CÜIUJACJJJJd'IrHJJIWU r I'ÃJ *jiiî' J-'qa'î' "'-VJ'II'Ã' -'~"'"I"-"Jf'L-"ÄI'I'J I|._i›.i r [î ' *:i: :117._1 1:" î i" 1:" .Jrf ~j*'IIiII..I' ;Ja-'zit * [|-' ' ii ,wr'i :iziig f i-'i'îziiçîi'vgi 11|i;._ii"I._i<'fî:^ i" i._i._i:'i'i;i[î i._iv' ii Mr i 1J i fr i.i'iw "Tîhif iii l i i it i Ü pwnw i iîF'îi`JPq Wfq af 'i i i ° f 'iîi tiqtqf wttu wîit'nnhn:i~1ûiuzi HHJJild'rf J'I'YISJlH'I' -:'a:eqq wl'›° fvvalit'fv.)]1t Abl versiyon 2- Agir Zincir proteini (N73D / C ucu lizini silinmis) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEW MGWMNPNSGNTDYAQKFQGRVTMTRQISISTAYIELSSLRSEDTAVY YCARDMVAANTDYYFYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCS RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIEKTISKTKGQPREPQVYTLFPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPG Ab2 versiyon 2- Agir Zincir proteini (N73D / C ucu lizini silinmis) QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEW MGWMNPNSGYTGYAQKFQGRVTMTRETSISTAYMEMSSLRSEDTAVY YCARDIVAANTDYYFYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCS RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPC PAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNW YVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVS NKGLPAPIBKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWBSNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPG Ab3 versiyon 2- Agir Zincir proteini QVHLVQSGAEVKKPGASVKVSCKÃSGYTFTSYGISWVRQAPGQGLEW MGWLSTYSGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTÄVY (C ucu lizini silinmis) YCARGNFYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSEST AALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEV Abl versiyon 2- 53 Agir Zincir Degisken Bölgesi QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEW MGWMNPNSGNTDYAQKFQGRVTMTREISISTAYIELSSLRSEDTAVY YCARDMVAANTDYYFYYGMDVWGQGTTVTVSS Ab2 versiyon 2- 54 Agir Zincir Degisken Rölnpqi QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYEINWVRQATGQGLEW MGWMNPNSGYTGYAQKFQGRVTMTRETSISTAYMEMSSLRSEDTAVY YCARDIVAANTDYYFYYGMDVWGQGTTVTVSS ELISA deneyleri, degisken bölgelerini içeren antikorlar farkli FC bölgelerine sahip Abl veya Ab2 (veya Abl veya Ab2'nin N73D varyanti) kullanilarak çesitli formatlarda (düsük aviditeli format için Yakalamali (capture) ELISA; çözelti fazi formati için Sandviç ELISA ve kati hal avidite formati için Direkt ELISA) gerçeklestirilmistir. Abl ve Ab2'nin her biri, insan IgG2 kökenli CHl, CH2, CH3 domenlerini içerir. Burada kullanildigi sekliyle "Abl" ve "Abl IgGZ WT" terimleri ayni antikoru ifade eder. Benzer sekilde "AbZ" ve "Ab2 IgG2 WT" terimleri ayni antikoru ifade eder. CHl domenine, karmayi azaltmak için (pozisyon 228'de bulunan) bir Ser'den Pro'ya mutasyona sahip insan IgG4'ten mentese, N baglantili glikozilasyon alani elimine etmek için (pozisyon 297'de bulunan) lgG4'ten CH2 Asn'den Gln'ye mutasyona sahip insan domeni ve insan IgGl'den CH3 domenine kaynastirilmistir Abl veya Ab2'nin (veya Abl veya Ab2'nin N73D varyantinin) degisken bölgelerini içerir. "IgG4P agly / IgGl" çerçevesi, US yayinlanmis patent basvurusu numarasi US ELISA sonuçlari, çikarilmasinin, N73D ornatmasi yoluyla glikozilasyon alaninin modifiye edilmis antikorlarin OSMR'ye baglanmasini etkilemedigini göstermistir. Bkz. Tablo lO. Yakalamali Sandviç (EC50) Antikor Direkt (EC50) nM Abl N73D IgG4P agly / IgGl Ab2 N73D IgG4P agly / IgGl Baglanma çalismalari, BIAcore yöntemi kullanilarak gerçeklestirilmistir. Farkli Fc bölgelerine sahip Abl veya Ab2'nin (Abl veya Ab2'nin N73D varyantinin) degisken bölgelerini içeren antikorlar, üreticinin protokollerine göre bir CM4 çipi (GE lifesciences) üzerinde immobilize edilmistir. Çözünebilir OSMR, analit olarak kullanilmistir. N73D ornatmasi yoluyla Abl ve Ab2'de glikosilasyon alaninin kaldirilmasi, baglanma afinitelerini gelistirmistir. Abl için ornatma, Kon hizini gelistirirken, Ab2 için Koff hizini gelistirmistir. Bkz. Tablo Antikor Kon (M-ls-l) Koff(1/s) KD (M) Fab fragmanlarinin stabilitesi, antikorlarin termal açiliminin degerlendirilmesiyle belirlenmistir. Fab fragmanlarinin yüksek erime sicakligi, artan stabilite ile dogrudan iliskilidir. Diferansiyel taramali flüorimetri deneyleri ile degerlendirildigi üzere, Ab2 üzerindeki glikozilasyon alanlarinin N73D ornatilmasiyla kaldirilmasi, Fab fragmanlarinin termal stabilitesini etkilememistir ve Abl üzerinde küçük etkiler göstermistir. Bkz. Tablo 12. Fab Tm Standart Hata Antikor (Santigrat) (Santrigat) Ab2 N73D Modifiye edilmis anti-OSMR antikorlarinin insan OSMR araciligiyla sinyallemeyi bloke etme kabiliyeti degerlendirilmistir. Modifiye edilmis antikorlar, IL31, OSM veya hattinda çogalmayi inhibe etme kabiliyetleri bakimindan degerlendirilmistir. Sonuçlar, her bir antikor için ICSO degeri ile birlikte asagida Tablo 13 ve 14'te sunulmustur. Sonuçlar, modifiye edilmis Abl ve Ab2 versiyonlarinin, OSM ve IL-3l aracili sinyallemesine karsi güçlü inhibitörler oldugunu dogrular. Antikor Abl N73D IgG4P agly / IgGl Antikor Ab2 N73D <110 SEKANS LISTESI BIOGEN IDEC MA INC. Arnett V.d.. <120 ONKOSTATIN M RESEPTÖRÜ ANTIJENI BAGLAYICI PROTEINLER <130 <160 <210 <21l <212 <213 <220 <221 <223 <400 Patentln versiyon 3.5 Homo sapiens MISC_FEATURE Insan OSMR <210 2 <211 <212 <213 <220 <22l <223 <400 2 MISC_FEATURE Macaca fascicularis Sinomolgus maymunu OSMR <210 3 <211 <212 <213 <220 <221 <223 <400 3 Homo sapiens misc_feature Abi Agir zinciri <210 4 <21l <212 <213 <220 <221 <223 <400 4 Homo sapiens misc_feature Ab2 Agir zinciri <210 5 <211 <212 <213 <220 <221 <223 <400 5 Homo sapiens misc_feature Ab3 Agir zinciri <210 6 <211 <212 <213 <220 <221 <223 <400 6 9939CCt939 99309909t9 Homo sapiens MISC_FEATURE Abl Agir zinciri <210 <211 <212 <213 <220 <221 <223 <400 Met Leu Asp Ser Asp Gly Ser Phe Phe Asp Lys Ser Arg Trp Gln Gln Gly Asn Homo sapiens MISC_FEATURE Ab2 Agir zinciri Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 435 440 <210 <21l <212 <213 <220 <221 <223 <400 Homo sapiens MISC_FEATURE Ab3 Agir zinciri Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys <210 9 <211 126 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Abl Agir zinciri degisken bölgesi <400 9 <210 10 <2ll 12 <212 <213 <220 <221 <223 <400 10 Homo sapiens MISC_FEATURE Ab2 Agir zinciri degisken bölgesi Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 25 30 Glu Ile Asn Trp Val Arg Gln Ala Thr Gly Gln Gly Lev Glu Trp Met 40 45 Gly Trp Met Asn Pro Asn Ser Gly Tyr Thr Gly Tyr Ala Gln Lys Phe 50 55 60 Gln Giy Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Met Ser Ser Lev Arg Ser Glu Asp Thr Ala Vai Tyr Tyr Cys 85 90 95 Ala Arg Asp Ile Val Ala Ala Asn Thr Asp Tyr Tyr Phe Tyr Tyr Gly 100 105 110 Met Asp Val Trp Gly Gln Gly Thr Thr Vai Thr Vai Ser Ser 115 120 125 <210 11 <211 119 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Ab3 Agir zinciri degisken bölgesi <400 11 Gln Val His Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 40 45 Gly Trp Leu Ser Thr Tyr Ser Gly Asn Thr Asn Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Arg Gly Asn Phe Tyr Tyr Tyr Gly Met Asp 100 105 <210 <211 <212 <213 <220 <221 <223 <400 Homo sapiens MISC_FEATURE Abl Agir zinciri CDRl <210 <211 <212 <213 <220 <221 <223 <400 Homo sapiens MISC_FEATURE Ab2 Agir zinciri CDRl <210 <2ll <212 <213 <220 <221 <223 <400 Homo sapiens MISCIFEATURE Ab3 Agir zinciri CDRl <210 <211 <212 <213 <220 <221 <223 <400 Trp Met Asn Pro Asn Ser Giy Asn Thr Asp Tyr Ala Gln Lys Phe Gln <210 <211 <212 <213 <220 <221 <223 <400 Homo sapiens MISC_FEATURE Abl Agir zinciri CDR2 Homo sapiens MISC_FEATURE Ab2 Agir zinciri CDR2 Trp Met Gly Trp Met Asn Pro Asn Ser Gly Tyr Thr Gly Tyr Ala Gln 1 5 10 15 <210 17 <211 17 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Ab3 Agir zinciri CDR2 <400 17 Trp Leu Ser Thr Tyr Ser Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln 1 5 10 15 <2lO 18 <211 17 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Abl Agir zinciri CD3 <400 18 Asp Met Val Ala Ala Asn Thr Asp Tyr Tyr Phe Tyr Tyr Gly Met Asp 1 5 10 15 <210 19 <211 17 <212 PRT <213 Homo sapiens <220 <221 <223 <400 Asp Ile Val Ala Ala Asn Thr Asp Tyr Tyr Phe Tyr Tyr Gly Met Asp <210 <211 <212 <213 <220 <221 <223 <400 Gly Asn Phe Tyr Tyr Tyr Gly Met Asp Val <210 <211 <212 <213 <220 <221 <223 <400 MISC_FEATURE Ab2 Agir zinciri CDR3 Homo sapiens MISC_FEATURE Ab3 Agir zinciri CDR3 Homo sapiens misc_feature Abl Hafif Zinciri <210 22 <211 648 <212 <213 <220 <221 <223 <400 22 <210 23 <211 648 Homo sapiens misc_feature Ab2 Hafif Zinciri <212 <213 <220 <221 <223 <400 23 <210 24 <21l <212 <213 <220 <221 <223 <400 24 Homo sapiens misc_feature Homo sapiens MISC_FEATURE Ab3 Hafif Zinciri Abl Hafif Zinciri <210 25 <211 216 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Ab2 Hafif Zinciri <400 25 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn 25 30 Thr Val Asn Trp Tyr His Gin Leu Pro Gly Thr Ala Pro Lys Leu Leu 40 45 <210 <21l <212 <213 <220 <221 <223 <400 Homo sapiens MISC_FEATURE Ab3 Hafif Zinciri Gln Ile Vai Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 40 45 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Pro Ile Thr Phe Gly Gln Giy Thr Arg Leu Glu Ile Lys Arg Thr Val 100 105 110 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys 115 120 125 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg 130 135 140 Glu Ala Lys Val Gln Trp Lys Vai Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Giu Ser Vai Thr Giu Gln Asp Ser Lys Asp Ser Thr Tyr Ser 165 170 175 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys 180 185 190 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr 195 200 205 Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210 27 <211 <212 <213 <220 <221 <223 <400 Homo sapiens MISC_FEATURE Abi Hafif Zinciri variable Gln Ser Val Leu Thr Gln Pro Pro Ser Arg Vai Thr Ile Ser Cys Ser Gly Ser Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Ser Lys Ser Giy Thr Ser Ala Ser Ser Glu Asp Glu Ala Asp Tyr Phe Cys Asn Gly Val Val Phe Gly Gly Gly Thr <210 <21l <212 <213 <220 <221 <223 <400 100 105 Homo sapiens MISC_FEATURE Ab2 Hafif Zinciri variable Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Arg Vai Thr Ile Ser Cys Ser Giy Ser Asn Thr Val Asn Trp Tyr His Gln Leu Pro Gly Gly Ser Lys Ser Gly Ser Ser Ala Ser Leu ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Asp Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val <210 <211 <212 <2l3 <220 <221 <223 <400 100 105 Homo sapiens MISC_FEATURE Ab3 Hafif Zinciri variable Glu Ile Val Leu Thr Gin Ser Pro Gly Thr Leu Ser Leu Ser Pro Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser 25 30 Tyr Leu Ala Trp Tyr Gin Gin Lys Pro Gly Gin Ala Pro Arg Leu 40 45 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gin Tyr Gly Ser Ser 85 90 95 Pro Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys Arg 100 105 110 <210 30 <211 13 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Abi Hafif Zinciri CDRl <400 30 Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Thr Val Ser <210 31 <211 13 <212 PRT <213 Homo sapiens <220 <221 MISCIFEATURE <223 Ab2 Hafif Zinciri CDRl <400 31 Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn Thr Val Asn <210 32 <211 12 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Ab3 Hafif Zinciri CDRl <400 32 Arg Ala Ser Gin Ser Val Ser Ser Ser Tyr Leu Ala <210 33 <211 7 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Abl Hafif Zinciri CDR2 <400 33 <210 34 <211 7 <212 PRT <213 Homo sapiens <220 <221 MISCIFEATURE <223 Ab2 Hafif Zinciri CDR2 <400 34 <210 35 <211 7 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Ab3 Hafif Zinciri CDR2 <400 35 <210 36 <211 11 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Abl Hafif Zinciri CDR3 <400 36 Ala Ala Leu Asp Asp Ser Leu Asn Gly Val Val <210 37 <211 11 <212 PRT <213 Homo sapiens <220 <221 MISCIFEATURE <223 Ab2 Hafif Zinciri CDR3 <400 37 Ser Thr Trp Asp Asp Ser Leu Asp Gly Val Val <210 38 <211 10 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Ab3 Hafif Zinciri CDR3 <400 38 Gln Gln Tyr Gly Ser Ser Pro Pro Ile Thr <210 39 <211 252 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Insan OSM <400 39 Phe Ser Lys Trp Gly Glu Ser Pro Asn Arg Ser Arg Arg His Ser Pro 210 215 220 His Gln Ala Leu Arg Lys Gly Val Arq Arg Thr Arg Pro Ser Arg Lys Giy Lys Arg Leu Met Thr Arg Gly Gln Leu Pro Arg 245 250 <210 40 <211 196 <212 PRT <2l3 Macaca fascicularis <220 <221 MISC_FEATURE <223 Sinomolgus maymunu OSM proteini <400 40 Gln Arg Lys Leu Glu Gly Cys Ser Phe Leu Arg Gly Tyr His Arg Phe Met His Ser Val Gly Arg Val Phe Ser Lys Trp Gly Glu Ser Pro Asn <210 41 <211 164 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Insan IL-31 <400 41 <210 42 <211 138 <212 PRT <213 Macaca fascicularis <220 <221 MISC_FEATURE <400 42 <210 43 <211 662 <212 PRT <213 Homo sapiens <220 <22l <223 <400 MISC_FEATURE Insan IL-31RA Leu Lys Arg Lys Thr Ser Tyr Ile Val Gln Vai Met Ala Ser Thr Ser 500 505 510 Ala Gly Gly Thr Asn Gly Thr Ser Ile Asn Phe Lys Thr Leu Ser Phe 515 520 525 Ser Val Phe Glu Ile Ile Leu Ile Thr Ser Leu Ile Gly Gly Gly Leu 530 535 540 Leu Ile Leu Ile Ile Leu Thr Val Ala Tyr Gly Leu Lys Lys Pro Asn Lys Leu Thr His Leu Cys Trp Pro Thr Val Pro Asn Pro Ala Glu Ser 565 570 575 Ser Ile Ala Thr Trp His Giy Asp Asp Phe Lys Asp Lys Leu Asn Leu 580 585 590 Lys Glu Ser Asp Asp Ser Val Asn Thr Glu Asp Arg Ile Leu Lys Pro 595 600 605 Cys Ser Thr Pro Ser Asp Lys Leu Val Ile Asp Lys Leu Val Val Asn 610 615 620 Phe Gly Asn Val Leu Gln Glu Ile Phe Thr Asp Glu Ala Arg Thr Gly Gln Glu Asn Asn Leu Gly Gly Glu Lys Asn Gly Thr Arg Ile Leu Ser 645 650 655 <210 44 <21l 649 <212 PRT <213 Macaca fascicularis <220 <221 misc_feature <223 Sinomolgus maymunu IL-ZlRA <400 44 Met Met Trp Thr Trp Ala Leu Trp Met Phe Pro Leu Leu Cys Lys Phe 1 5 10 15 Gly Leu Ala Ala Leu Pro Ala Lys Pro Glu Asn Ile Ser Cys Val Tyr <210 45 <211 918 <212 PRT <213 Homo sapiens <220 <221 MISC_FEATURE <223 Insan gp130 <400 45 Arg Ser Lys Gln Val Ser Ser Val 835 840 Lys Gln Gln Ile Ser Asp His Ile 850 855 Met Lys Met Phe Gln Glu Val Ser Thr Glu Gly Gln Val Glu Arg Phe Thr Asp Giu Gly Met Pro Lys Ser <210 <211 <212 <213 <220 <221 <223 <400 Macaca fascicularis MISC_FEATURE Sinomolgus maymunu gplBO Gly Gly Ty:: Met 875 880 TR TR TR TR TR TR TR TR TR TR TR
TR2018/15608T 2013-05-30 2014-05-30 Onkastatin m reseptörü antijeni bağlayıcı proteinler. TR201815608T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361829082P 2013-05-30 2013-05-30

Publications (1)

Publication Number Publication Date
TR201815608T4 true TR201815608T4 (tr) 2018-11-21

Family

ID=51059621

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/15608T TR201815608T4 (tr) 2013-05-30 2014-05-30 Onkastatin m reseptörü antijeni bağlayıcı proteinler.

Country Status (23)

Country Link
US (7) US9663571B2 (tr)
EP (4) EP3456743B1 (tr)
JP (6) JP6243521B2 (tr)
KR (3) KR102652165B1 (tr)
CN (4) CN118271441A (tr)
AU (5) AU2014273966B2 (tr)
BR (1) BR112015029643B1 (tr)
CA (1) CA2910732A1 (tr)
DK (2) DK3456743T3 (tr)
EA (1) EA201592285A1 (tr)
ES (3) ES2973474T3 (tr)
HU (2) HUE056580T2 (tr)
IL (3) IL317484A (tr)
MX (3) MX380702B (tr)
MY (1) MY199321A (tr)
NZ (2) NZ753995A (tr)
PL (3) PL3971212T3 (tr)
PT (2) PT3004167T (tr)
SG (1) SG11201508829QA (tr)
SI (2) SI3004167T1 (tr)
TR (1) TR201815608T4 (tr)
WO (1) WO2014194274A2 (tr)
ZA (1) ZA201508064B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
WO2016120625A1 (en) * 2015-01-29 2016-08-04 Isis Innovation Limited Biomarker
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
MX2019012255A (es) 2017-04-11 2019-12-05 Kiniksa Pharmaceuticals Ltd Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).
CA3073537A1 (en) * 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
BR112020021739A2 (pt) * 2018-04-25 2021-01-26 Kiniksa Phamaceuticals, Ltd. tratamento de doenças ou distúrbios de pele pela liberação do anticorpo anti-osmrbeta
WO2020036833A1 (en) * 2018-08-13 2020-02-20 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
EP3877408A4 (en) * 2018-11-06 2022-08-24 University of Miami COMPOSITIONS AND PRODUCTION OF RECOMBINANT AAV VIRUS VECTORS CAPABLE OF IN VIVO GLYCOENGINEERING
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
TWI904261B (zh) * 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
CA3227171A1 (en) * 2021-07-30 2023-02-02 Zhiqiang KU Osmr-specific monoclonal antibodies and methods of their use
CN119451570A (zh) * 2022-06-29 2025-02-14 百奥赛图(北京)医药科技股份有限公司 一种osm、osmr、il31ra和/或il31基因修饰的非人动物
CN120858115A (zh) 2023-03-07 2025-10-28 基因泰克公司 抗抑瘤素M受体β抗体用于治疗肺纤维化疾病或病症的方法
US20250101117A1 (en) * 2023-09-01 2025-03-27 Genentech, Inc. Methods for treating inflammatory bowel disease
CN120230206A (zh) * 2023-12-29 2025-07-01 苏州爱科百发生物医药技术有限公司 抑瘤素M受体β结合抗体及其用途

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US233A (en) 1837-06-14 Improvement in plows
US4447A (en) 1846-04-04 Car- wheel
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5681930A (en) 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ZA912136B (en) * 1990-03-29 1992-11-25 Bristol Myers Squibb Co Anti-oncostatin m monoclonal antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
WO2000018938A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
DK1961811T3 (da) 2002-01-18 2010-11-08 Zymogenetics Inc Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
EP2840089A1 (en) 2002-01-18 2015-02-25 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP4803789B2 (ja) * 2004-02-03 2011-10-26 独立行政法人科学技術振興機構 疼痛を処置するための薬学的組成物
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
PT1730191E (pt) 2004-03-30 2011-10-04 Glaxo Group Ltd Imunoglobulina que se liga a hosm
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
JP2008521828A (ja) 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
US7572896B2 (en) * 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
EP1888637A2 (en) 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
ATE535529T1 (de) 2005-08-09 2011-12-15 Millennium Pharm Inc Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
EP2749571A3 (en) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
WO2007100367A1 (en) 2006-03-01 2007-09-07 Thomson Licensing Device and method for generating a media package
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
ES2548714T3 (es) 2006-09-01 2015-10-20 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y procedimientos de uso
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
ME03057B (me) 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
US9475876B2 (en) 2012-05-11 2016-10-25 Wakayama Medical University Anti oncostatin M receptor beta antibody used for treating atopic dermatitis
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
HUE056580T2 (hu) 2013-05-30 2022-02-28 Kiniksa Pharmaceuticals Ltd Onkosztatin-M-receptor antigénjét kötõ fehérjék
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
MX2019012255A (es) 2017-04-11 2019-12-05 Kiniksa Pharmaceuticals Ltd Formulacion estable de anticuerpo contra el receptor de oncostatina m (osmr).

Also Published As

Publication number Publication date
US20170218076A1 (en) 2017-08-03
US20160137739A1 (en) 2016-05-19
MX2015016304A (es) 2016-03-21
CN105555803A (zh) 2016-05-04
JP6606122B2 (ja) 2019-11-13
PL3004167T3 (pl) 2019-01-31
NZ753995A (en) 2022-07-01
IL267382A (en) 2019-08-29
MY199321A (en) 2023-10-24
CA2910732A1 (en) 2014-12-04
JP7682335B2 (ja) 2025-05-23
IL287824B1 (en) 2025-01-01
US10421813B2 (en) 2019-09-24
JP2025114801A (ja) 2025-08-05
US12122837B2 (en) 2024-10-22
HUE040548T2 (hu) 2019-03-28
HK1249522A1 (zh) 2018-11-02
EP3971212B1 (en) 2023-12-27
CN105555803B (zh) 2019-09-10
NZ713636A (en) 2022-07-01
JP6243521B2 (ja) 2017-12-06
EP4349864A3 (en) 2024-06-26
AU2017228686B2 (en) 2019-11-14
ES2692657T3 (es) 2018-12-04
PT3456743T (pt) 2021-10-27
US20250230250A1 (en) 2025-07-17
US20180002429A1 (en) 2018-01-04
PL3971212T3 (pl) 2024-05-27
CN118271441A (zh) 2024-07-02
PT3004167T (pt) 2018-11-13
KR20180086295A (ko) 2018-07-30
IL317484A (en) 2025-02-01
ZA201508064B (en) 2019-07-31
EP3971212A1 (en) 2022-03-23
EP3971212C0 (en) 2023-12-27
EP4349864A2 (en) 2024-04-10
CN107513105B (zh) 2019-08-16
WO2014194274A3 (en) 2015-03-12
CN107513105A (zh) 2017-12-26
AU2020200980A1 (en) 2020-02-27
EP3004167A2 (en) 2016-04-13
ES2973474T3 (es) 2024-06-20
KR102652165B1 (ko) 2024-03-27
US9663571B2 (en) 2017-05-30
AU2014273966A1 (en) 2015-11-12
JP2017140056A (ja) 2017-08-17
JP2024095814A (ja) 2024-07-10
HK1224310A1 (zh) 2017-08-18
KR102258460B1 (ko) 2021-06-02
AU2017228686A1 (en) 2017-10-05
JP7474817B2 (ja) 2024-04-25
JP2020022482A (ja) 2020-02-13
DK3004167T3 (en) 2018-11-12
US20220056144A1 (en) 2022-02-24
CN110511279A (zh) 2019-11-29
EP3004167B1 (en) 2018-07-25
MX2020003503A (es) 2020-07-22
US9593163B2 (en) 2017-03-14
MX380702B (es) 2025-03-12
IL267382B (en) 2021-12-01
JP2016520619A (ja) 2016-07-14
JP2022180573A (ja) 2022-12-06
MX351127B (es) 2017-10-03
CN110511279B (zh) 2024-03-29
IL287824B2 (en) 2025-05-01
PL3456743T3 (pl) 2022-03-07
US20170008958A1 (en) 2017-01-12
ES2895824T3 (es) 2022-02-22
HK1221961A1 (en) 2017-06-16
BR112015029643B1 (pt) 2023-12-12
SI3004167T1 (sl) 2019-01-31
KR20160011644A (ko) 2016-02-01
HUE056580T2 (hu) 2022-02-28
EP3456743B1 (en) 2021-08-18
KR20210064400A (ko) 2021-06-02
AU2022202503A1 (en) 2022-05-12
US9738721B1 (en) 2017-08-22
WO2014194274A2 (en) 2014-12-04
EA201592285A1 (ru) 2016-05-31
IL287824A (en) 2022-01-01
SG11201508829QA (en) 2015-12-30
BR112015029643A2 (pt) 2017-09-26
AU2014273966B2 (en) 2017-08-31
KR101882366B1 (ko) 2018-07-30
EP3456743A1 (en) 2019-03-20
SI3456743T1 (sl) 2022-01-31
AU2020200980B2 (en) 2022-04-28
AU2022202503B2 (en) 2025-08-14
AU2025267425A1 (en) 2025-12-04
US20190359724A1 (en) 2019-11-28
DK3456743T3 (da) 2021-09-27

Similar Documents

Publication Publication Date Title
TR201815608T4 (tr) Onkastatin m reseptörü antijeni bağlayıcı proteinler.
TWI846717B (zh) 辨識抗體-藥物結合物之藥物部位的蛋白質
JP5677744B2 (ja) ヒトＤｅｌｔａ様リガンド４に対するヒト抗体
KR102025035B1 (ko) 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
AU2021215230B2 (en) Anti-tenascin c antibodies and uses thereof
US20200386770A1 (en) Monoclonal antibodies against human pd-l1 and uses thereof
KR102734387B1 (ko) 항-알파-시누클레인 항체 및 이의 용도
JP7270557B2 (ja) 抗ｒｏｂｏ２抗体、組成物、方法、およびその使用
CN113156134B (zh) 用于检测人白介素23的elisa试剂盒及检测方法
JP7829590B2 (ja) 複雑な多段階の抗体相互作用を解明するための方法
CN118078986A (zh) 一种抗Nectin-4单克隆抗体药物或其衍生物的特异性结合剂及其应用
KR102653734B1 (ko) 캄필로박터 속 박테리아를 검출하기 위한 항체 및 검사 디바이스
RU2765809C2 (ru) Усовершенствованные фармакокинетические анализы для одиночных вариабельных доменов иммуноглобулина
CN118725112B (zh) 抗人sCD14-ST蛋白的单克隆抗体及其应用
JP7526728B2 (ja) 抗ｖｅｇｆ抗体のｖｅｇｆ－ｒ１への結合阻害を改善する方法
CN113135994B (zh) 一种激活型抗ox40抗体、生产方法及应用
RU2812765C2 (ru) Антитела к альфа-синуклеину и варианты их применения
JP6202652B1 (ja) 抗エクオール抗体組成物及びその利用
WO2022268200A1 (zh) 针对密蛋白18.2的抗体及其用途
CN120463805A (zh) 一种抗白喉毒素突变体抗体及其制备方法和应用
CN121532425A (zh) 靶向pd-l1的免疫球蛋白单可变结构域
HK40054347B (zh) 抗alpha-突触核蛋白抗体及其用途
JP2011007664A (ja) 抗体のスクリーニング方法